Certara (NASDAQ:CERT) Shares Gap Down – Here’s What Happened

Certara, Inc. (NASDAQ:CERT)’s stock price gapped down before the market opened on Thursday . The stock had previously closed at $6.03, but opened at $5.73. Certara shares last traded at $5.7540, with a volume of 535,302 shares changing hands.

Wall Street Analyst Weigh In

Several equities analysts recently commented on CERT shares. Craig Hallum cut their price target on shares of Certara from $10.00 to $8.00 and set a “hold” rating on the stock in a report on Tuesday, May 12th. TD Cowen reiterated a “buy” rating on shares of Certara in a report on Thursday, February 26th. Stephens cut their price target on shares of Certara from $10.00 to $9.00 and set an “overweight” rating on the stock in a report on Tuesday, May 12th. Leerink Partners reiterated an “outperform” rating and set a $10.00 price target on shares of Certara in a report on Thursday, February 26th. Finally, BMO Capital Markets cut their price target on shares of Certara from $7.00 to $6.00 and set a “market perform” rating on the stock in a report on Tuesday, May 12th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Certara presently has an average rating of “Hold” and an average price target of $8.85.

Certara Price Performance

The firm’s 50-day moving average price is $5.60 and its two-hundred day moving average price is $7.10. The stock has a market cap of $885.97 million, a PE ratio of -56.95 and a beta of 1.49. The company has a current ratio of 1.88, a quick ratio of 1.88 and a debt-to-equity ratio of 0.28.

Certara (NASDAQ:CERT) last announced its quarterly earnings results on Monday, May 11th. The company reported $0.09 earnings per share for the quarter, missing the consensus estimate of $0.11 by ($0.02). Certara had a positive return on equity of 3.52% and a negative net margin of 3.60%.The business had revenue of $106.92 million during the quarter, compared to analysts’ expectations of $106.13 million. During the same period in the previous year, the company posted $0.14 EPS. Certara’s revenue for the quarter was up .8% on a year-over-year basis. Certara has set its FY 2026 guidance at 0.350-0.410 EPS. On average, equities analysts expect that Certara, Inc. will post 0.24 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Certara

Several hedge funds have recently modified their holdings of CERT. Northwestern Mutual Wealth Management Co. lifted its position in shares of Certara by 2,733.3% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 2,975 shares of the company’s stock worth $26,000 after purchasing an additional 2,870 shares during the period. Osaic Holdings Inc. lifted its position in shares of Certara by 50.7% in the 2nd quarter. Osaic Holdings Inc. now owns 3,491 shares of the company’s stock worth $41,000 after purchasing an additional 1,175 shares during the period. Tower Research Capital LLC TRC lifted its position in shares of Certara by 499.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,917 shares of the company’s stock worth $69,000 after purchasing an additional 4,930 shares during the period. Chicago Partners Investment Group LLC purchased a new stake in shares of Certara in the 1st quarter worth approximately $78,000. Finally, Kera Capital Partners Inc. purchased a new stake in shares of Certara in the 1st quarter worth approximately $80,000. Hedge funds and other institutional investors own 73.96% of the company’s stock.

Certara Company Profile

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.